One of the leading causes of disability in the U.S. is major depressive disorder (MDD), affecting more than 16.1 million adults each year. Another perhaps more shocking statistic is that about 80% of those people never seek treatment, for various reasons. However, one of the main reasons why so many individuals fail to seek treatment is because of the stigma associated with having a mental health condition. A stigma that, unfortunately, is alive and thriving in our society today.
Last year, on June 23, twelve young boys—members of the Wild Boars youth soccer team—and their coach were unexpectedly trapped inside an underground cave system in Thailand. When flood water quickly and unexpectedly rose, their exploration went from fun and exciting to frightening and dangerous...and fast. The water blocked off their exit and trapped them inside, with their only option to go deeper into the cave. They were trapped in the cave for over two weeks before cave rescue teams from China, Myanmar, Laos, Australia, the UK, and the United States finally reached them on July 10.
An expectant mother is about to experience extreme lifestyle changes, on top of the immediate emotional and physical stress of childbirth. Dealing with these newfound challenges—sleep deprivation, the responsibility of nurturing a newborn, and the underlying stress of unrealistic expectations—can send a new mother into a debilitating downward spiral.
The recent FDA approval of the use of esketamine for treatment-resistant depression means many Americans suffering will soon find relief. The drug, Spravato, was approved for patients who have failed to respond at all to at least two other antidepressant medications. After years of clinical trials, the decision to officially approve Spravato took a month before a panel of experts voted in favor of the new treatment. Since treatment-resistant depression plagues so many among us, this new treatment has generated tremendous hope for depression sufferers, their loved ones, and their mental health clinicians.
Depression is a mental disorder that affects 350 million people world wide. According to a medical paper published by Louisiana State University Health Sciences Center, people in the United States 18 years and older make up 4.6% of those 350 million. The study, which surveyed 600,000—or 0.1836%—of the US population, concluded that those who spend more than 6 hours in front of a screen were at a greater risk for depression.
Since it was developed in 2016, we’ve blogged several times about esketamine—the isomer of ketamine being developed by Janssen Pharmaceuticals, designed to rapidly alleviate the symptoms of treatment-resistant depression. Esketamine, which will be administered intranasally, was granted breakthrough medication status by the FDA and fast-tracked for approval. And the time for approval is here.
Over the past several years, ketamine has received a growing amount of media attention. As a treatment for depression, no other medication has shown this much promise since Prozac was discovered in the 1980s. Ketamine has been hailed as “miraculous,” and a “wonder drug,” alleviating depressive symptoms in up to 70% of patients…even those who failed to respond to depression treatment after depression treatment. What’s even more spectacular is the speed in which ketamine works—patients know whether ketamine will work for them after only 1-2 infusions.
For many women, giving birth is the most joyous event of their lives. But, every year, for more than 3 million women in the U.S., child birth results in the development of postpartum depression—and it can be devastating for mother and child alike. Most cases of postpartum depression are resolved within a matter of months, with such treatments as talk therapy, antidepressants, and ketamine infusions. However, some cases of postpartum depression can worsen in time, ultimately increasing the mother’s risk for developing chronic, severe depression.
There is no one-size-fits-all solution for depression. Even though 17% of people will suffer from depression over the course of their lives, modern medicine is still searching for a comprehensive solution. Traditional antidepressant medications are the first line of treatment for depression, though they are only effective for about 40-70% of patients, depending on what source you quote. In recent years, ketamine infusions have emerged as one of the most effective depression treatment available, offering hope for even the most debilitating cases of depression and providing relief to 70% of patients. Inspired by the way ketamine works to treat depression, several pharmaceutical companies are well underway developing new medications that may revolutionize the way we treat this mental health disorder.
The importance of diagnosing and treating mental health disorders is incontestable: with the country’s suicide rate growing at a faster rate than ever—and with a number of celebrity suicides bringing much-needed awareness to the matter—there is no argument that mental wellbeing is an important health concern that deserves our attention and care. However, the physical implications of depression and anxiety are much less talked about—even though a new study shows that they can be as severe as the health concerns caused by obesity or smoking.
As one of Colorado’s leading ketamine clinics, we see first-hand the impact that mental health disorders can have on an individual. We see the pain that prevents a patient from engaging in their favorite hobbies or activities, or that keeps them home in bed rather than at the office, or that lets the dishes pile up in the sink day after day because they just can’t bring themselves to perform even the most mundane of household tasks.
The holiday season evokes something different in everyone. Some people experience a childlike elation, enjoying the well-wishes and whimsy of the season. Others look forward to time spent with family, the freedom to check out of work and surround themselves with those they love. However, for many people, the holidays are a major trigger for anxiety and depression.
For those suffering from PTSD, traditional treatments oftentimes fall short when it comes to alleviating symptoms. Antidepressants are effective in only about 40 percent of patients, and benzodiazepines—while commonly prescribed as a treatment for PTSD may actually worsen symptoms. A study recently published in the Journal of Clinical Psychiatry revealed that PTSD patients who were prescribed benzodiazepines were almost twice as likely to attempt suicide. It goes without saying that PTSD patients need and deserve a more effective suite of treatment options.
More than 300 million people in the world suffer from clinical depression, but 50% of them will never seek treatment. Rather, these people suffer from such symptoms as sadness, inability to concentrate, and loss of appetite—with limited hope for improvement. Many individuals diagnosed with depression never admit that they need treatment in the first place. However, there are still others who recognize that they need depression treatment, but feel it is inaccessible to them.
The discovery of ketamine for depression is absolutely the biggest breakthrough we’ve seen in depression treatment in over 50 years. Since the early part of the century, study after study has demonstrated ketamine’s substantial rapid-acting effect in reducing depressive symptoms. Not surprisingly, the media have taken notice:Time Magazine, Scientific American, Business Insider, Forbes, Psychology Today, and National Public Radio are only a few of the media outlets that have reported on the use of ketamine for depression and the advancements that have been made as a result of ongoing research. It seems that, every day, there is a new discovery about how ketamine works to treat depression…
In the United States, at least one physician commits suicide every day. It’s the highest suicide rate of any profession, taking the lives of up to 40 physicians per every 100,000—a rate that is twice the national average. And until now, no one has really talked about it. However, a new documentary seeks to take a closer look at the deadly trend in medical care.
More than 20 veterans commit suicide every day. Organizations such as 22 Kill and Active Heroes have brought a lot of awareness to the mental healthcare needs of those who have served our nation, but the truth is, no matter how aware we are of suicidality in veterans, they are still choosing to take their own lives at a rate higher than any other population of people.
When it comes to depression, no one is exempt—especially those at the tops of their industries. In fact, as a result of the stress that goes hand-in-hand with their careers, plus the personal characteristics that have enabled them to become successful in the first place, C-level executives, business leaders and entrepreneurs are perhaps more susceptible to depression than other people.
In April 2018, we shared some promising information about a Yale School of Medicine study that found ketamine to be highly effective in reducing the symptoms of depression in a 16-year old patient suffering from suicidal ideations. After having declared himself “hopeless about the prospect of psychiatric improvement,” the patient was treated with ketamine infusions. His condition quickly improved to the point where he could be discharged from his inpatient psychiatric facility and resume his schooling. This study, however, was limited in scope, as it only presented the results from this one patient.
Opioid addiction has increased by over 500% in the last seven years—there is hardly an American who doesn’t know someone who is addicted, who has been directly affected by opiate addiction, or who is addicted himself. In response to this epidemic, the CDC has enacted changes to the way doctors may administer and prescribe opiates. This has left many chronic pain patients frustrated and in fear of losing access to the medications that keep them functional.